CORRECTING and REPLACING Luma Therapeutics Announces Data Presentations from Studies of the Illuvinate System for the Treatment for Plaque Psoriasis at AAD Annual Meeting

MILLBRAE, Calif.–(BUSINESS WIRE)–URL in the Luma Therapeutics boilerplate of release dated Feb. 27, 2019
should read www.lumatherapeutics.com.

The corrected release reads:

LUMA THERAPEUTICS ANNOUNCES DATA PRESENTATIONS FROM STUDIES OF THE
ILLUVINATE SYSTEM FOR THE TREATMENT FOR PLAQUE PSORIASIS AT AAD ANNUAL
MEETING

Luma Therapeutics, a company dedicated to eradicating suffering from
inflammatory skin disease, today announced that new data from studies of
the company’s illuvinate™ System will be presented at the American
Academy of Dermatology Annual Meeting taking place March 1 to 4 in
Washington, D.C.

Clinical trials conducted to demonstrate the safety and efficacy of the
product will be presented by Tina Bhutani, M.D., of the UCSF Medical
Center in San Francisco, Calif., as part of the following presentations
(all times local):

  • Phototherapy
    Presented by Henry W. Lim, M.D., Anna Chien,
    M.D., Benjamin Stoff, M.D., Elizabeth A. Buzney, M.D., and Tina
    Bhutani, M.D.
    Friday, March 1, 9:00 a.m., Room 201
  • Psoriasis and Atopic Dermatitis: Advances in Immunology and Therapy
    Presented
    by Jashin J. Wu, M.D., Emma Guttman, M.D., Ph.D., Lawrence F.
    Eichenfield, M.D., Paul Steven Yamauchi, M.D., Ph.D., Tina Bhutani,
    M.D.
    Saturday, March 2, 3:30 p.m., Salon H

Luma Therapeutics will also hold a cocktail reception hosted by founder
and CEO Evan Anderson and Chief Medical Officer Jeffrey Sugarman, M.D.,
on Thursday Feb. 28, 4:30 to 7:00 p.m., at Convivial, 801 O Street NW,
Washington, D.C. Click
here
to RSVP.

The company will be exhibiting at the conference in booth #2347.

About the illuvinate™ System

The FDA-cleared illuvinate System is an innovative treatment
designed to provide lasting relief from psoriasis symptoms. Inspired by
the Goeckerman Regimen, a 100-year-old proven therapy that results in
long periods of remission lasting over a year.1 However this
treatment is only available at a handful of specialized centers and
often requires multiple day-long clinic visits over a period of weeks,
creating barriers to widespread adoption. Luma Therapeutics has
redesigned the key elements of the Goeckerman Regimen to make it
available to patients in their own home.

Illuvinate has been demonstrated to reduce local inflammation, rehydrate
the skin and restore normal skin cells. The system includes patented
hydrating technology, a narrowband UV LED light system, and a
proprietary app-based dosing algorithm. The therapy is applied for just
minutes each day over a six-week period from the comfort and convenience
of home. The system can now be prescribed either by a dermatologist or
via Luma’s telehealth provider, HealthLens.

About Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical
technology company committed to developing innovative and convenient
therapies for the millions of people around the world suffering from
inflammatory skin disease. In collaboration with Mayo Clinic, Luma
Therapeutics developed the FDA-cleared illuvinate™ System to offer
patients with psoriasis an effective treatment option that can be used
at home. The company has also been supported by StartX accelerator and
the Rosenman Institute at QB3. For more information visit www.lumatherapeutics.com.

1 Gupta, Rishu, et al. “The Goeckerman Regimen for the
Treatment of Moderate to Severe Psoriasis.” Journal of
Visualized Experiments
, no. 77, 2013, doi:10.3791/50509.

Contacts

Durae Hardy
Health+Commerce
Tel: 707.337.1903